A Growing Body of Clinical Data Showing the Potential of iNKT Cell Therapy – MiNK Therapeutics
MiNK Therapeutics shared a post on LinkedIn about a paper by Benjamin Garmezy et al. published in Oncogene:
“MiNK Therapeutics’ allogeneic iNKT cell therapy, agenT-797, continues to gain recognition as a promising approach in solid tumors.
A new peer-reviewed case study published in Oncogene describes a meaningful clinical response in a patient with metastatic, treatment-refractory testicular cancer following treatment with agenT-797 in combination with anti–PD-1 therapy.
This case builds on a growing body of clinical data showing the potential of iNKT cell therapy to reshape the tumor microenvironment and drive immune responses in cancers unresponsive to standard treatments.
Read the full publication.”
Title: Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor
Authors: Benjamin Garmezy, Joseph E. Grossman, Jennifer Buell, Thiago Favano, Justin Stebbing, Steven O’Day, Marco A. Purbhoo, Dhan Chand, F. Anthony Greco
You can read the Full Article in Oncogene.
More posts featuring MiNK Therapeutics.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023